An exploratory biomarker study of immunecheckpoint inhibitors using tumor tissue and peripheral blood

Conditions

lung cancer, and melanoma

Yuichi Ozawa, Yasuhiro Koh, Ryota Shibaki, Yuhei Harutani, Hiroaki Akamatsu et al. (11 authors)

Cancer Immunology Immunotherapy2024-11-026 citations

Tumor expression of cGAS, not STING, negatively impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS ≥50.

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami et al. (18 authors)

Journal of Clinical Oncology2021-05-20

10.1200/jco.2021.39.15_suppl.e21048

CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50

Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami et al. (21 authors)

Cancer Science2020-10-2115 citations

10.1111/cas.14705

Abstract 5595: Predictive impact of sequential evaluation of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab

Yasuhiro Koh, Hiroaki Akamatsu, Keita Mori, Kuninobu Kanai, Atsushi Hayata et al. (11 authors)

Cancer Research2018-07-01

10.1158/1538-7445.am2018-5595

Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.

Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N.

2017-11-21302 citations

10.1016/j.lungcan.2017.11.019

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed as lung cancer or melanoma, and can be provide tissue and blood samples with this study. 2. Patients who will be treated with immunecheckpoint inhibitors 3. To obtain written informed consent from patients

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To examine the utility of tissue and blood biomarkers before and during treatment.	—

Countries

Japan

Contacts

Public ContactHiroaki and Yasuhiro Akamatsu and Koh

Wakayama Medical University Respiratory Medicine and Medical Oncology

h-akamat@wakayama-med.ac.jp073-441-0619

Outcome results